letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...910111213141516171819...100101»
  • ||||||||||  letrozole / Generic mfg.
    Paraneoplastic Dermatomyositis : Case Report (Poster area) -  Jan 18, 2024 - Abstract #ESGO2024ESGO_866;    
    She was treated with neoadjuvant chemotherapy followed by left Patey and letrozole hormonal therapy...She will have locoregional radiotherapy at a dose of 40 Gy and a BOOST of 13.35 Gy.Results Clinical outcomes showed no significant improvement and persistent pruritic dermatological lesions.Conclusion Paraneoplastic syndromes are a factor in both the diagnosis and monitoring of certain tumours. When dermatomyositis occurs in patients with a history of breast cancer, a relapse must be sought as a priority
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Cervical Metastasis Of Breast Carcinoma: A Rare Presentation (Poster area) -  Jan 18, 2024 - Abstract #ESGO2024ESGO_789;    
    First-line therapy consisted of Ribociclib and Letrozole. Conclusion Despite the rarity of the presentation, patients with breast cancer may should benefit from a thorough gynecologic screening for metastasis during follow-up.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., tamoxifen / Generic mfg.
    Journal:  An Updated Insight into Phytomolecules and Novel Approaches used in the Management of Breast Cancer. (Pubmed Central) -  Jan 17, 2024   
    The current literature helps to know the available drugs i.e. phytoconstituents or novel drug delivery like nanoparticle, microsphere, micelles, liposomes and neosomes. The literature has been taken from PubMed, Google Scholar, SciFinder, or other internet sites.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Enrollment closed, Metastases:  ABIGAIL: ABemaciclib, ET  (clinicaltrials.gov) -  Jan 17, 2024   
    P2,  N=162, Active, not recruiting, 
    Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jun 2026 | Trial primary completion date: Dec 2023 --> Mar 2025 Recruiting --> Active, not recruiting
  • ||||||||||  letrozole / Generic mfg., clomifene citrate / Generic mfg.
    Journal:  Efficacy of Letrozole vs Clomiphene Citrate for induction of ovulation in women with polycystic ovarian syndrome. (Pubmed Central) -  Jan 10, 2024   
    P2/3
    Hot flushes were higher in clomiphene group (31.8% vs 12.7% p-value 0.001) while fatigue (30.9% vs 8.1% p-value 0.000) and dizziness (21.8% vs 10.0% p-value 0.029) was higher with letrozole but these were well tolerated. Letrozole is better treatment choice than clomiphene citrate in PCOS women with infertility in terms of pregnancy and live birth rate.ClinicalTrials.gov Identifier: NCT05702957.
  • ||||||||||  letrozole / Generic mfg., thyroxine / Generic mfg.
    Enrollment change, Trial completion date, Trial primary completion date:  Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism (clinicaltrials.gov) -  Jan 2, 2024   
    P=N/A,  N=200, Recruiting, 
    However, differences on results between therapies for postmenopausal patients were not statistically significant. N=500 --> 200 | Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Oct 2023 --> Jan 2024
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Myo-Inositol for Infertility in PCOS (clinicaltrials.gov) -  Dec 31, 2023   
    P=N/A,  N=168, Recruiting, 
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date, Metastases:  POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) -  Dec 31, 2023   
    P2,  N=19, Active, not recruiting, 
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial completion date, Trial primary completion date:  Roll-over Study to Allow Continued Access to Ribociclib (clinicaltrials.gov) -  Dec 28, 2023   
    P4,  N=137, Recruiting, 
    The combination of a degressive MPA dose with LE proved effective in reducing the total MPA dosage with comparable premature LH surge and pregnancy outcomes in women undergoing the PPOS protocol. Trial completion date: Feb 2028 --> Sep 2029 | Trial primary completion date: Jan 2028 --> Aug 2029
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Administration of adipose-derived mesenchymal stem cell conditioned medium improves ovarian function in polycystic ovary syndrome rats: involvement of epigenetic modifiers system. (Pubmed Central) -  Dec 20, 2023   
    In the present study, we aimed to investigate the effects of ASC and ASC-CM on epigenetic regulators, steroidal function and folliculogenesis in the letrozole-induced PCOS rats. Based on the measurement of the oral glucose tolerance test and physical parameters including body weight, estrus cycle pattern as well as ovary dimensions, PCOS-induced rats in sham and control (CTRL) groups showed signs of reproductive dysfunctions such as lack of regular estrus cyclicity, metabolic disorders such as increased ovary dimension, body weight and blood glucose level alteration which were improved especially by ASC-CM administration.
  • ||||||||||  defactinib (VS-6063) / Verastem, avutometinib (VS-6766) / Verastem
    Enrollment open:  RAMP 301: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (clinicaltrials.gov) -  Dec 19, 2023   
    P3,  N=270, Recruiting, 
    Based on the measurement of the oral glucose tolerance test and physical parameters including body weight, estrus cycle pattern as well as ovary dimensions, PCOS-induced rats in sham and control (CTRL) groups showed signs of reproductive dysfunctions such as lack of regular estrus cyclicity, metabolic disorders such as increased ovary dimension, body weight and blood glucose level alteration which were improved especially by ASC-CM administration. Not yet recruiting --> Recruiting
  • ||||||||||  limantrafin (CB-103) / Cellestia Biotech
    Enrollment change, Trial termination:  CAILA: CB-103 Plus NSAI In Luminal Advanced Breast Cancer (clinicaltrials.gov) -  Dec 19, 2023   
    P2,  N=2, Terminated, 
    Not yet recruiting --> Recruiting N=80 --> 2 | Active, not recruiting --> Terminated; Sponsor decision
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  The effect of hydrogen-rich water on letrozole-induced polycystic ovary syndrome in rats. (Pubmed Central) -  Dec 17, 2023   
    SNPs of aromatase gene predict risk of metastasis and AI-related toxicity in ER+ early BC, opening an opportunity for better treatment individualization. The study findings demonstrate that hydrogen-rich water reduces the number of cysts and oxidative damage in rats with PCOS.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
    Journal, Metastases:  Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer? (Pubmed Central) -  Dec 17, 2023   
    A recent phase Ib/II trial evaluated the combination of tucatinib, letrozole, and palbociclib in patients with HR+/HER2+ metastatic breast cancer, demonstrating a manageable safety profile and encouraging efficacy data. An all-oral, chemotherapy-free regimen is an appealing strategy, and could be a possible maintenance or primary therapy option in select patients.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial primary completion date, Metastases:  ABIGAIL: ABemaciclib, ET  (clinicaltrials.gov) -  Dec 15, 2023   
    P2,  N=160, Recruiting, 
    This article summarizes the FDA's decision-making and data supporting the approval of ribociclib in male patients with breast cancer, and discusses regulatory insights. Trial primary completion date: Sep 2023 --> Jan 2024
  • ||||||||||  letrozole / Generic mfg.
    LETROZOLE-INDUCED PARONYCHIA () -  Dec 13, 2023 - Abstract #WRMC2024WRMC_717;    
    Treatment was ultimately changed to a fluconazole 200 mg tablet two times weekly, topical betamethasone dipropionate 0.05% cream application twice daily, and topical ketoconazole 2% cream application twice daily...The primary hypothesis regarding the mechanism of cancer treatment-induced paronychia is vasodilation, which may increase blood flow, resulting in greater vascular permeability. With increased vascular permeability, leakage can be sustained in chronic inflammation, leading to edema and reduced vascular perfusion, thereby increasing the risk of infection.
  • ||||||||||  letrozole / Generic mfg.
    Enrollment open:  Study of Letrozole in Recurrent Gliomas (clinicaltrials.gov) -  Dec 12, 2023   
    P1,  N=39, Recruiting, 
    With increased vascular permeability, leakage can be sustained in chronic inflammation, leading to edema and reduced vascular perfusion, thereby increasing the risk of infection. Active, not recruiting --> Recruiting
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  GOG-3039: Abemaciclib and Letrozole to Treat Endometrial Cancer (clinicaltrials.gov) -  Dec 12, 2023   
    P2,  N=53, Active, not recruiting, 
    Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  lerociclib (G1T38) / Walvax, Pepper Bio
    Trial completion date, Trial termination, Metastases:  A Study of Lerociclib in Participants With Advanced Breast Cancer (clinicaltrials.gov) -  Dec 6, 2023   
    P2,  N=100, Terminated, 
    Not yet recruiting --> Recruiting Trial completion date: May 2026 --> Nov 2023 | Active, not recruiting --> Terminated; The study is being closed based on corporate changes at EQRx and is not related to any efficacy or safety issues with lerociclib.